{"denoms":[{"counts":[{"groupId":"BG000","value":"574"},{"groupId":"BG001","value":"576"},{"groupId":"BG002","value":"1150"}],"units":"Participants"}],"groups":[{"description":"Participants received 160 mg of enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.","id":"BG000","title":"Enzalutamide + Androgen Deprivation Therapy (ADT)"},{"description":"Participants received enzalutamide matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.","id":"BG001","title":"Placebo + Androgen Deprivation Therapy (ADT)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.0","value":"69.5"},{"groupId":"BG001","spread":"8.4","value":"69.5"},{"groupId":"BG002","spread":"8.2","value":"69.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"year"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"574"},{"groupId":"BG001","value":"576"},{"groupId":"BG002","value":"1150"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"83"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"504"},{"groupId":"BG001","value":"514"},{"groupId":"BG002","value":"1018"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"49"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"155"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"466"},{"groupId":"BG001","value":"460"},{"groupId":"BG002","value":"926"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"53"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"220"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"423"}],"title":"Low"},{"measurements":[{"groupId":"BG000","value":"354"},{"groupId":"BG001","value":"373"},{"groupId":"BG002","value":"727"}],"title":"High"}]}],"description":"High volume of disease was defined as metastases involving the viscera or, in the absence of visceral lesions, 4 or more bone lesions, at least 1 of which was in a bony structure beyond the vertebral column and pelvic bone. Low volume was anything that wasn't considered high volume by definition provided.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT)","title":"Volume of Disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"471"},{"groupId":"BG001","value":"474"},{"groupId":"BG002","value":"945"}],"title":"None"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}],"title":"1 to 5 cycles"},{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"180"}],"title":"6 cycles"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT","title":"Prior Docetaxel Therapy Use","unitOfMeasure":"Participants"}],"populationDescription":"All Randomized Participants"}